Form 4: Pasithea Therapeutics Director Emer Leahy Acquires Stock Options

Director Emer Leahy acquired stock options in Pasithea Therapeutics Corp. on March 1, 2024, according to a Form 4 filing with the SEC.

Summary

• On March 1, 2024, Emer Leahy, a director of Pasithea Therapeutics Corp., acquired stock options to purchase 7,500 shares of common stock at an exercise price of $8.34.
• The options vest in three annual installments starting one year from the grant date, contingent on continued service as a director.
• The options expire on February 28, 2034.
• The filing also notes a 1-for-20 reverse stock split that Pasithea Therapeutics Corp. effected on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of an insider transaction. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The acquisition of stock options is a typical form of executive compensation.

Stakeholder Impact

• Shareholders may view the director's stock option acquisition as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Form 4, Emer Leahy, Pasithea Therapeutics, director, KTTA, reverse stock split, equity awards, beneficial ownership